Kimberly J. Butterwick, MD, FAAD

Cosmetic Laser Dermatology, San Diego, CA, USA

Dermatologic surgery, cosmetic dermatology

• What is the role of non-surgical chin augmentation in full-face rejuvenation? 8s
• What can dermatologists learn about new modalities for the sagging neck? 47s
• What new developments in injectable fillers were discussed at the AAD 2019 Annual Meeting? 100s

Hassan I. Galadari, MD, FAAD

UAE University, Abu Dhabi, United Arab Emirates

Fillers, cosmetic dermatology

• When considering dermal fillers, what concerns are most important for you as a dermatologist, and for your patients? 8s
• What cosmetic dermatology advances are of greatest interest to dermatologists, researchers, and patients? 90s
• What trends in cosmetic dermatology did you see in 2018, and what do you anticipate for 2019? 215s

Brian A. Ginsberg, MD, FAAD

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Transgender patients

• What dermatology issues are particularly relevant to transgender patients? 8s
• What management challenges do you encounter when treating transgender patients? 43s
• Is it possible that dermatology procedures currently deemed cosmetic or elective will be considered medically necessary for transgender patients in the future? 79s

Nellie Konnikov, MD, FAAD

Boston University School of Medicine, Boston, MA, USA

Field cancerization therapies, photodynamic therapy

• What can dermatologists learn about field cancerization therapies at the 2019 AAD Annual Meeting? 8s
• Can photodynamic therapy be a useful modality for field cancerization in elderly and high-risk immunosuppressed patients? 51s
• What new developments in photodynamic therapy are featured at the AAD 2019 Annual Meeting, and how can dermatologists use this knowledge to improve patient care? 128s
• How are photodynamic therapy candidates selected, and how are therapeutic goals set? 191s

Mark G. Lebwohl, MD, FAAD

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Psoriasis, psoriatic arthritis

• What are the best methods for determining which drug is best suited for the specific patient? 8s
• What are new developments in the treatment of psoriatic arthritis? 158s

Boris D. Lushniak, MD, MPH, FAAD

School of Public Health, University of Maryland, College Park, MD, USA

The dermatologist in modern society

• What topics does the AAD 2019 Annual Meeting cover about the changing role of the dermatologist in contemporary society? 8s
• How might dermatologists influence the way that health systems provide patient care? 213s
• How can dermatologists balance the challenges of applying technical advances, containing costs, and improving outcomes to provide high-quality patient care? 264s

Crystal L. Mackall, MD

Stanford University, Stanford, CA, USA

Engineering T cells for cancer therapy

• After many decades of research, genetically engineered T cells are demonstrating unprecedented activity against B-cell malignancies. Could the engineered immune cells also prove effective against solid tumors? 8s
• What is the current state-of-the-art of engineered immune cells for the treatment of cancer? 95s
• Antigen escape and downregulation have emerged as major issues impacting the durability of CAR T cell therapy. What is their incidence and what are the ways to overcome these obstacles in order to improve clinical outcomes? 173s

Kristian Reich, MD, PhD

University Medical Center Hamburg-Eppendorf, Germany

Psoriasis, atopic dermatitis

• What are your highlights from the AAD 2019 Annual Meeting in the areas of psoriasis and atopic dermatitis? 8s

Jerry Shapiro, MD, FAAD

NYU Langone Medical Center, New York, NY, USA

Hair disorders

• What are new developments for the quantification of progress when evaluating patient outcomes? 8s
• What emerging therapies to treat hair loss were presented at the AAD 2019 Annual Meeting? 83s
• How does treating hair loss in women differ from treating hair loss in men? 186s
• How does the cause of hair loss impact the treatment options considered by physician and patient? 260s

Daniel M. Siegel, MD, MS, FAAD

SUNY Downstate Medical Center University, Brooklyn, NY, USA

Dermatologic surgery pearls: optimizing safety, satisfaction, efficiency

• What technological innovations were discussed at the AAD 2019 Annual Meeting? 8s
• What are some valuable opportunities for AAD member dermatologists to collaborate with international colleagues to improve clinical practice? 264s
• How can dermatologists enhance patient safety and patient-centered outcomes? 333s

Jashin J. Wu, MD, FAAD

Dermatology Research and Education Foundation, Irvine, CA, USA

Joint AAD-NPF Psoriasis Guidelines

• What are some updates on the 2019 Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NPF) Psoriasis Guidelines? 8s
• In what ways do the 2019 Joint AAD-NPF Psoriasis Guidelines differ from previous guidelines? 111s

Robin Farmanfarmaian

Professional speaker, career coach & entrepreneur, Palo Alto, CA, USA

Patient empowerment in the digital age

• We live in times of great social, scientific, and technological transformation. Do you think that it's possible to dismantle, then redesign existing healthcare systems? 8s
• How can physicians help patients understand the current medical revolution driven by innovative technologies? 34s
• Patients have traditionally been passive. In your book, The Patient as CEO, you describe technologies disrupting medicine, putting patients in control of their own healthcare. How will this impact the future of medicine? 72s

Neil H. Shear, MD, FRCPC

President, Canadian Dermatology Association

Drug safety, patient safety

• Welcome message 8s
• How does drug safety fit into the AAD 2019 Annual Meeting curriculum? 30s
• How can dermatologists inform patients about safety issues? 85s
• What do you feel are hot topics in dermatology that deserve action? 150s

Julie Powell, M.D., FRCPC

Présidente sortante, Association canadienne de dermatologie

Pédodermatologie, anomalies vasculaires, dermatite atopique

• Avec quels récents développements dans le domaine de la pédodermatologie, les dermatologues canadiens peuvent-ils se familiariser grâce à la conférence annuelle AAD 2019? 8s
• Quelles sont certaines des nouvelles perspectives dans le traitement de la dermatite atopique? 40s
• Quelles sont les thérapies émergentes ciblées pour les anomalies vasculaires? 81s

Kirk Barber, MD, FRCPC

University of Calgary

Eczema, psoriasis, medical publishing

• What new developments for eczema treatment were covered at the AAD 2019 Annual Meeting? 8s
• What are some new developments in the use of biologics for the treatment of psoriasis? 54s
• What are some priorities for editors in medical publishing? 100s